Dr. David Kilner: Weight Loss Reduces Risk of Psoriatic Arthritis
Dr. Wala’a Hafez While weight loss is well-known for its benefits in preventing heart disease, diabetes, and high blood pressure, scientific evidence suggests it may offer additional advantages for patients with psoriasis. Psoriasis is not merely a chronic skin condition causing red patches and bothersome scales; its effects can extend to the joints, impacting patients’ quality of life and mobility. Although treatment often focuses on controlling skin symptoms, recent research indicates that adopting a healthy lifestyle, with weight management at its core, may help slow disease progression and reduce the risk of complications. In this context, two recent studies, presented at the annual meeting of the Psoriasis and Psoriatic Arthritis Research and Evaluation Group and published on Medscape, reported promising results. They showed that weight loss following a psoriasis diagnosis may be associated with a significant reduction in the risk of developing psoriatic arthritis, while also highlighting the potential role of GLP-1 receptor agonists in weight management. This could open new avenues for preventing disease complications alongside traditional treatments.
◄ Obesity Increases Inflammation Dr. David Kilgore, a rheumatologist and assistant professor at the University of California, Los Angeles, clarified that obesity is a prominent factor increasing the likelihood of psoriasis progressing to psoriatic arthritis. He explained that adipose tissue is not merely an energy store but also secretes inflammatory substances known as cytokines and adipokines, which contribute to chronic systemic inflammation. This may facilitate the transition of the disease from the skin to the joints. He added that previous studies have confirmed a clear association between increased weight and a higher risk of psoriatic arthritis. However, the question that remained was whether weight loss after a psoriasis diagnosis could reduce this risk.
◄ A Detailed Study to Answer the Question To address this, researchers conducted a retrospective study involving 10,721 psoriasis patients receiving care at the University of California, none of whom had psoriatic arthritis at the start of the study. During the first year after psoriasis diagnosis, 1,032 patients developed psoriatic arthritis. The results showed that individuals who lost 5% or more of their body weight had a 37% lower risk of developing the disease compared to those who did not achieve this level of weight loss.
◄ Greater Weight Loss, Greater Benefit The findings did not stop there; the study revealed a clear dose-response relationship based on the amount of weight lost:
● Losing 5% of body weight reduced the risk by 37%.
● Losing 10% of body weight was associated with a 49% risk reduction.
● Losing 15% of body weight was associated with a risk reduction of up to 69%.
Researchers noted that the decrease in statistical significance at higher rates of weight loss does not mean the effect disappears, but rather reflects the small number of patients who managed to lose such high percentages of their weight. They emphasized that maintaining weight loss is as important as losing it initially. Among the study’s key findings, patients who maintained their weight loss for up to two years experienced a 68% reduction in the risk of developing psoriatic arthritis. Researchers described this result as a “strong signal” warranting further research, suggesting that sustained weight maintenance may be as crucial as initial weight loss in reducing disease progression risk.
◄ A Second Study In a second study presented by researcher Elena Feng from the University of California, San Francisco, researchers utilized a large American database (TriNetX) containing the electronic health records of millions of patients. The study included over 46,000 psoriasis patients, comprising 22,431 who used GLP-1 medications and 23,826 who did not.
◄ Significant Reduction in Arthritis Risk The results showed that users of GLP-1 medications were less likely to develop psoriatic arthritis compared to non-users. The risk reduction was:
● 43% during the first year.
● 26% after ten years of follow-up.
When analyzing only the newer medications, such as semaglutide and tirzepatide, the risk reduction after ten years was 36%. The benefit was observed across various groups, including:
● Patients with obesity.
● Patients with type 2 diabetes.
● Both men and women.
◄ A Definitive Result? Despite the encouraging findings, researchers stressed that current studies cannot prove a direct causal relationship. The reduced risk may be due to weight loss itself rather than a direct pharmacological effect of GLP-1 medications on the immune system or inflammation. Dr. Kilgore noted that his team attempted to answer this question, but the number of GLP-1 users in the study was insufficient to reach a definitive conclusion. He added that the next step would be expanding the study to include all University of California hospitals, which would increase the sample size to approximately two and a half times its current size. This could help determine whether these medications provide protection independent of weight loss.
◄ How Does Obesity Weaken the Body’s Defenses? Researchers believe that obesity leads to increased secretion of inflammatory substances that chronically activate the immune system, potentially accelerating the transition of psoriasis from the skin to the joints. Conversely, weight loss may reduce this systemic inflammation, improve the body’s insulin sensitivity, and lower levels of various inflammatory markers, explaining the reduced risk of psoriatic arthritis.
◄ What Do These Results Mean for Patients? Although these studies do not definitively prove that weight loss prevents psoriatic arthritis, they provide important practical evidence that weight management may be a fundamental part of the treatment plan for psoriasis patients, alongside medication and medical follow-up. They also open the door for future research to determine whether GLP-1 medications have a direct preventive effect against psoriatic arthritis or if the benefit primarily stems from their ability to achieve sustained weight loss.
◄ Study Summary The study concluded with several key points:
1. Losing 5% of body weight after a psoriasis diagnosis reduced the risk of psoriatic arthritis by 37% within one year.
2. The greater the percentage of weight loss, the greater the risk reduction.
3. Maintaining lost weight for two years was associated with a 68% reduction in disease risk.
4. Users of GLP-1 medications recorded lower rates of psoriatic arthritis, but it has not yet been proven that this effect is independent of weight loss.
5. Longer and larger studies are needed to prove the causal relationship and determine the true role of these medications in disease prevention.
